We provide venture, private equity or debt finance to regional businesses with growth ambition.
Providing the best possible support to our portfolio businesses and partners.
Striving to be the first choice for our investors, investees and colleagues.
The dedicated home of Mercia’s exclusive portfolio interviews, deep-dive blogs, insightful podcasts and educational webinars; all delivered by business leaders and industry experts.
Discover more about our Group including our approach to corporate governance and driving shareholder value
Business Description
PsiOxus Therapeutics is a developer of novel therapeutics for solid tumours through its proprietary targeted oncolytic virus and tumour-specific immuno-gene therapy platform (T-SIGn).
Rationale for Investment
To be a world-leading cancer gene therapy company, developing an internal programme and entering into commercial partnerships to advance a oncolytic virus pipeline.
Paolo Paoletti – Non-executive Chair
John Beadle – CEO
© 2022 Mercia Asset ManagementWebsite by 438